[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"WeiShi\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636743","phase-4-letermovir-prophylaxis-duration-guided-by-cmv-specific-t-cell-monitoring-after-allo-hsct-100636743",false,"NCT07569653","Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.","A Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Letermovir Prophylaxis Duration Guided by Dynamic Monitoring of Specific T-cells for Preventing Cytomegalovirus Infection in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation in China.","Inclusion Criteria:\n\n1. Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n2. CMV serostatus of the recipient is positive (R+).\n3. Aged 18 years or older.\n4. Expected survival \\> 6 months.\n5. Provision of signed informed consent.\n\nExclusion Criteria:\n\n* 1.Active CMV infection or CMV disease at the time of screening.\n\n  2.Known hypersensitivity to Letermovir or its excipients.\n\n  3.Severe hepatic or renal impairment.\n\n  4.Pregnant or breastfeeding women.","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of a personalized strategy for discontinuing Letermovir (a drug used to prevent Cytomegalovirus \\[CMV\\] infection) based on the recovery of the patient's own immune system.\n\nCytomegalovirus (CMV) is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Currently, Letermovir is typically given as a standard prevention for about 100 days post-transplant. However, some patients may recover their CMV-specific immunity earlier, while others may need longer protection.\n\nIn this study, researchers will use a dynamic monitoring technology (QuantiFERON-CMV) to detect the level of CMV-specific T-cells in patients. Participants will be randomly assigned to either the experimental group or the control group:\n\nExperimental Group: Letermovir discontinuation will be guided by T-cell recovery. If the test shows that the patient's CMV-specific T-cells have recovered, Letermovir may be stopped earlier than the standard 100 days.\n\nControl Group: Patients will receive the standard Letermovir prophylaxis for approximately 100 days, regardless of T-cell status.\n\nThe study aims to determine if this immune-guided strategy can effectively prevent CMV infection while potentially reducing the duration of medication and associated costs, without increasing the risk of CMV disease.",[26,27,28,29],"Cytomegalovirus Infections","Cytomegalovirus Disease","Hematopoietic Stem Cell Transplantation","Graft vs Host Disease","RECRUITING","2026-05-27",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":34},"2025-10-30",{"date":38,"type":20},"2027-12",{"name":40,"class":41},"WeiShi","OTHER",12,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100637881","phase-2-a-prospective-study-of-madecassoside-tablets-in-sclerotic-chronic-graft-versus-host-disease-after-allo-hsct-100637881","NCT07606703","A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT","A Prospective, Multicenter, Single-Arm Phase 2 Study of Madecassoside Tablets Combined With Standard Therapy for Sclerotic Chronic Graft-versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign written informed consent;\n2. Age 14 to 65 years;\n3. Diagnosis of sclerotic chronic graft-versus-host disease (scl-cGVHD) according to the 2014 NIH consensus criteria, including superficial or deep skin sclerosis, fasciitis, or restricted joint mobility;\n4. Prior treatment history meeting at least one of the following:\n\n   * Received systemic corticosteroid therapy for ≥12 months and at least 1 additional systemic therapy; OR\n   * Received corticosteroid therapy and at least 2 additional systemic therapies;\n5. Karnofsky Performance Status (KPS) score ≥60;\n6. Absolute neutrophil count \\>1,000\u002FμL;\n7. Platelet count ≥50,000\u002FμL.\n\nExclusion Criteria:\n\n* 1\\. Total bilirubin \\>1.5 times the upper limit of normal; 2. Creatinine clearance \\\u003C30 mL\u002Fmin; 3. Uncontrolled infection; 4. Uncontrolled cardiovascular or pulmonary disease; 5. Any clinical condition that, in the investigator's judgment, makes the participant unsuitable for study participation.","14 Years","65 Years",{"count":53,"type":20},30,[55],"PHASE2","Sclerotic chronic graft-versus-host disease (scl-cGVHD) is a severe subtype of chronic GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by skin sclerosis, fascial involvement, and restricted joint mobility, leading to substantial functional impairment and reduced quality of life. Current standard therapies, including corticosteroids and other immunosuppressive agents, have limited efficacy in patients with refractory or steroid-dependent disease.\n\nMadecassoside tablets, a standardized extract of Centella asiatica, have demonstrated anti-inflammatory and anti-fibrotic properties in previous studies and may provide therapeutic benefit in fibrotic diseases.\n\nThis study is a prospective, multicenter, single-arm phase 2 clinical trial designed to evaluate the efficacy and safety of madecassoside tablets combined with standard therapy in patients with scl-cGVHD after allo-HSCT. Eligible participants will receive oral madecassoside tablets (0.2 g three times daily) in addition to standard treatment for 6 months. Clinical assessments will be performed at baseline and at weeks 4, 8, 12, and 24.\n\nThe primary endpoint is the improvement rate of skin and\u002For joint\u002Ffascia NIH cGVHD scores at 6 months according to the 2014 NIH consensus criteria. Secondary endpoints include overall cGVHD response rate, failure-free survival, non-relapse mortality, corticosteroid dose reduction, patient-reported outcomes, and safety assessments. Peripheral blood samples will also be collected to explore changes in inflammatory cytokines and lymphocyte subsets during treatment.",[58,29],"Chronic Graft-Versus-Host Disease","2026-05-18",{"date":61,"type":34},"2026-05-26",{"date":63,"type":34},"2025-09-01",{"date":65,"type":20},"2029-09-01",{"name":40,"class":41},1,""]